Anti-obesity effect of eucalyptus leaf extract containing oenothein B in healthy Japanese adults: a randomized, placebo-controlled, double-blind, parallel-group study

Authors

  • Keiichiro Sugimoto Research and Development Center, Nagaoka Co., Ltd., Ibaraki, Osaka 567-0005, Japan
  • Hiroyuki Fujisawa Tokyo Laboratory, Nagaoka Co., Ltd., Koto-ku, Tokyo 135-0015, Japan
  • Kazuya Nakagawa Research and Development Center, Nagaoka Co., Ltd., Ibaraki, Osaka 567-0005, Japan
  • Kazuo Yamamoto ORTHOMEDICO Inc., Bunkyo-ku, Tokyo 112-0002, Japan
  • Naoko Suzuki ORTHOMEDICO Inc., Bunkyo-ku, Tokyo 112-0002, Japan
  • Shin-ichiro Yamashita ORTHOMEDICO Inc., Bunkyo-ku, Tokyo 112-0002, Japan
  • Yuta Takahashi ORTHOMEDICO Inc., Bunkyo-ku, Tokyo 112-0002, Japan
  • Toshihiro Kakinuma ORTHOMEDICO Inc., Bunkyo-ku, Tokyo 112-0002, Japan
  • Asami Baba ORTHOMEDICO Inc., Bunkyo-ku, Tokyo 112-0002, Japan
  • Tsuyoshi Takara Medical Corporation Seishinkai, Takara Clinic, Shinagawa-ku, Tokyo 141-0022, Japan
  • Toshikazu Yamanouchi Diabetes Center, Kashiwa-Tanaka Hospital, Kashiwa, Chiba 277-0803, Japan

DOI:

https://doi.org/10.31989/ffhd.v12i5.927

Abstract

Background: Excessive ingestion of fructose can lead to obesity and related diseases. Eucalyptus leaf extract (ELE) contains oenothein B, which inhibits intestinal fructose absorption.

Objective: The antiobesity effects of ELE containing oenothein B were evaluated in healthy Japanese whose body mass index (BMI) was ≥ 23 and < 30 kg/m2.

Methods: A randomized, placebo-controlled, double-blind, parallel-group study was performed to evaluate the effect of ELE consumption, for 12 weeks at a 3.38 mg/day dose of oenothein B, on the abdominal visceral fat area (VFA) as the primary outcome. Results were compared to those of a placebo group.

Results: Of the 721 individuals who underwent screening, 198 were randomly allocated into two groups. A total of 95 subjects in the placebo group and 94 in the intervention group were established as the per-protocol set. VFA in the intervention group significantly decreased compared to that in the placebo group 12 weeks after initiating intervention. This reduction in VFA was considered to have clinical significance. Among the secondary outcomes, VFA, waist circumference, and muscle mass after 8 weeks, as well as body weight and BMI after 12 weeks, were significantly lower in the intervention group compared to the placebo group.

Conclusion: ELE containing oenothein B may be effective against obesity and related diseases by reducing VFA levels.

 

Keywords: human trial; Eucalyptus globulus; oenothein B; polyphenol; hydrolyzable tannin; ellagitannin; dietary fructose consumption; dietary survey; Calorie and Nutrition Diary; glucose transporter 5

Downloads

Published

2022-05-28

Issue

Vol. 12 No. 5 (2022): May 2022

Section

Research Articles

License

Any manuscripts or substantial parts of it, submitted to the journal must not be under consideration by or previously published in any other journal or citable form. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights or the rights of a third party. In submitting one's article in any form, the author has assigned the FFC publishing rights and has agreed to an automatic transfer of the copyright to the publisher. This is so that the FFC may create print option journals, for example, at the FFC’s discretion. If the author wishes to distribute their works by means outside of the FFC, for example within their community, they will have to place a request. 

 

Correspondence concerning articles published in Functional Foods in Health and Disease is encouraged. While derivative works (adaptations, extensions on the current work, etc.) are allowed, distribution of the modified material is not allowed without permission from the FFC.